Point-of-care testing (POCT) is highly required for enhanced patient outcomes with early/rapid diagnosis in an emergency situation or patient monitoring. Conventional lateral flow immunoassay (LFIA) sensors are not sometimes suitable for early diagnosis because of its low detection sensitivity. This technology enables highly sensitive detection (pg/mL level) of target biomarkers in 20 min. Based on the LFIA combined with a swellable polymer, the developed immunosensor shows an automated signal amplification after immunoassay and easy-to-use with a minimum user operation. It is suitable for rapid diagnosis in acute myocardial infarction (AMI) which requires POCT-based high-sensitivity detection of troponin I lower than 1 pg/mL.
Primary Application Area: Medical Devices
Technology Development Status: Prototype
Technology Readiness Level: TRL 5
Vetted Programs/Awards: Bill & Melinda Foundation Grants (2017)
Organization Type: Academic/Gov Lab
Showcase Booth #: 34
GOVT/EXTERNAL FUNDING SOURCES